Literature DB >> 31485851

High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?

Adam J Nelson1, Sam Mirzaee2, Stephen J Nicholls3.   

Abstract

Despite the widespread use of statins in the setting of high cardiovascular risk, many patients continue to experience clinical events. This highlights the need to identify additional therapeutic strategies for high-risk patients. Interest in the use of omega-3 polyunsaturated fatty acids to prevent cardiovascular disease has been high for several decades. Despite promising results from before the statin era, many clinical trials have produced disappointing findings regarding products containing conventional doses of omega-3 fatty acids. More recent clinical trials using high doses of omega-3 fatty acids in targeted populations have suggested potential benefit when targeting the risk driven by atherogenic dyslipidemia. We review the clinical implications of completed and ongoing trials.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31485851     DOI: 10.1007/s40256-019-00363-3

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  47 in total

1.  Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism.

Authors:  H Doi; K Kugiyama; H Oka; S Sugiyama; N Ogata; S I Koide; S I Nakamura; H Yasue
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

3.  Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.

Authors:  Brian A Ference; John J P Kastelein; Kausik K Ray; Henry N Ginsberg; M John Chapman; Chris J Packard; Ulrich Laufs; Clare Oliver-Williams; Angela M Wood; Adam S Butterworth; Emanuele Di Angelantonio; John Danesh; Stephen J Nicholls; Deepak L Bhatt; Marc S Sabatine; Alberico L Catapano
Journal:  JAMA       Date:  2019-01-29       Impact factor: 56.272

Review 4.  The forgotten majority: unfinished business in cardiovascular risk reduction.

Authors:  Peter Libby
Journal:  J Am Coll Cardiol       Date:  2005-10-04       Impact factor: 24.094

5.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

6.  Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction.

Authors:  Anne Langsted; Jacob J Freiberg; Børge G Nordestgaard
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

7.  Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol.

Authors:  Hwa Kyoung Shin; Yong Ki Kim; Ki Young Kim; Jeong Hyun Lee; Ki Whan Hong
Journal:  Circulation       Date:  2004-02-16       Impact factor: 29.690

8.  Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.

Authors:  Roxane M Mansouri; Eric Baugé; Philippe Gervois; Jamila Fruchart-Najib; Catherine Fiévet; Bart Staels; Jean-Charles Fruchart
Journal:  Circ Res       Date:  2008-07-24       Impact factor: 17.367

9.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245

10.  Triglyceride-rich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress.

Authors:  Ying I Wang; Ahmed Bettaieb; Chongxiu Sun; J Sherrod DeVerse; Christopher E Radecke; Steven Mathew; Christina M Edwards; Fawaz G Haj; Anthony G Passerini; Scott I Simon
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.